Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 6
1993 8
1994 18
1995 19
1996 34
1997 23
1998 30
1999 18
2000 31
2001 28
2002 16
2003 23
2004 19
2005 21
2006 13
2007 22
2008 20
2009 17
2010 19
2011 22
2012 18
2013 22
2014 11
2015 13
2016 18
2017 16
2018 10
2019 8
2020 14
2021 33
2022 27
2023 12
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Results by year

Filters applied: . Clear all
Page 1
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K, Colbert JD, Rock KL. Dhatchinamoorthy K, et al. Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021. Front Immunol. 2021. PMID: 33767702 Free PMC article. Review.
This allows CD8 T cells to identify pathological cells that are synthesizing abnormal proteins, such as cancers that are expressing mutated proteins. In order for many cancers to arise and progress, they need to evolve mechanisms to avoid elimination by CD8 T cells. …
This allows CD8 T cells to identify pathological cells that are synthesizing abnormal proteins, such as cancers that are expressing m …
Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
Tu Z, Li K, Ji Q, Huang Y, Lv S, Li J, Wu L, Huang K, Zhu X. Tu Z, et al. BMC Cancer. 2023 Feb 9;23(1):133. doi: 10.1186/s12885-022-10491-w. BMC Cancer. 2023. PMID: 36759763 Free PMC article.
TAP1 participates in tumor immunity, and is aberrantly expressed in multiple cancer types; METHODS: Transcriptome profiles were obtained from The Cancer Genome Atlas and Genotype-Tissue Expression databases. ...Single-cell analyses of TAP1 across ca …
TAP1 participates in tumor immunity, and is aberrantly expressed in multiple cancer types; METHODS: Transcriptome profiles wer …
Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer.
Shen M, Smith HA, Wei Y, Jiang YZ, Zhao S, Wang N, Rowicki M, Tang Y, Hang X, Wu S, Wan L, Shao ZM, Kang Y. Shen M, et al. Nat Cancer. 2022 Jan;3(1):60-74. doi: 10.1038/s43018-021-00280-y. Epub 2021 Nov 29. Nat Cancer. 2022. PMID: 35121988 Free PMC article.
Despite increased overall survival rates, curative options for metastatic breast cancer remain limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in poor prognosis breast cancer, where it promotes metastasis and therapy resistance t …
Despite increased overall survival rates, curative options for metastatic breast cancer remain limited. We have previously shown that …
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL Jr, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ. Powles T, et al. Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6. Epub 2022 Jan 10. Nat Med. 2022. PMID: 35013615 Free PMC article. Clinical Trial.
Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. ...Exploratory analysis linked progression-free survival in the atezolizumab arm with immune …
Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD …
Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.
Tabassum A, Samdani MN, Dhali TC, Alam R, Ahammad F, Samad A, Karpiński TM. Tabassum A, et al. J Mol Med (Berl). 2021 Sep;99(9):1293-1309. doi: 10.1007/s00109-021-02088-w. Epub 2021 May 28. J Mol Med (Berl). 2021. PMID: 34047812 Free PMC article.
The association of TAP1 in cancer progression remains mostly unknown and further study of the gene in relation with cancer need to conduct. ...An upregulation of TAP1 mRNA was demonstrated in various cancer types. This study reported a significa …
The association of TAP1 in cancer progression remains mostly unknown and further study of the gene in relation with cancer …
Downregulation of TAP1 and TAP2 in early stage breast cancer.
Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Henle AM, et al. PLoS One. 2017 Nov 1;12(11):e0187323. doi: 10.1371/journal.pone.0187323. eCollection 2017. PLoS One. 2017. PMID: 29091951 Free PMC article.
In this study, we investigated the immunohistochemical expression of TAP1 and TAP2 in 160 patients with breast cancer and correlated their expression levels with clinicopathologic parameters. ...Both TAP1 and TAP2 overexpression in breast cancer might …
In this study, we investigated the immunohistochemical expression of TAP1 and TAP2 in 160 patients with breast cancer and corr …
Clinical Significance of TAP1 and DLL4 Expression in Patients With Locally Advanced Gastric Cancer.
Segami K, Aoyama T, Hiroshima Y, Komori K, Hashimoto I, Watanabe H, Kano K, Nagasawa S, Nakazono M, Maezawa Y, Fujikawa H, Numata M, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Siozawa M, Yukawa N, Morinaga S, Rino Y, Masuda M, Miyagi Y, Saeki H, Oshima T. Segami K, et al. In Vivo. 2021 Sep-Oct;35(5):2771-2777. doi: 10.21873/invivo.12562. In Vivo. 2021. PMID: 34410967 Free PMC article.
BACKGROUND/AIM: Cancer stem cells (CSCs) are reported to associated with cancer metastasis, relapse, and chemoresistance. ...RESULTS: High TAP1 expression was associated with better overall survival compared to low TAP1 expression (p=0.004). ...
BACKGROUND/AIM: Cancer stem cells (CSCs) are reported to associated with cancer metastasis, relapse, and chemoresistance. ...R …
Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations.
Padariya M, Kote S, Mayordomo M, Dapic I, Alfaro J, Hupp T, Fahraeus R, Kalathiya U. Padariya M, et al. Comput Struct Biotechnol J. 2021 Sep 9;19:5072-5091. doi: 10.1016/j.csbj.2021.09.006. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34589184 Free PMC article.
In ER, the peptides are further processed and loaded on the major histocompatibility class (MHC) I molecules by the peptide loading complex (PLC). The TAP transporters are linked with the PLC; a target for cancers and viral immune evasion. But the mechanisms whereby the …
In ER, the peptides are further processed and loaded on the major histocompatibility class (MHC) I molecules by the peptide loading complex …
TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer.
Ling A, Löfgren-Burström A, Larsson P, Li X, Wikberg ML, Öberg Å, Stenling R, Edin S, Palmqvist R. Ling A, et al. Oncoimmunology. 2017 Aug 7;6(11):e1356143. doi: 10.1080/2162402X.2017.1356143. eCollection 2017. Oncoimmunology. 2017. PMID: 29147604 Free PMC article.
We used a gene expression array to search for potential mechanisms of tumor immune escape. One candidate gene identified was TAP1, involved in antigen presentation by MHC class I. TAP1 protein expression was evaluated by immunohistochemistry in 436 CRC patients of t …
We used a gene expression array to search for potential mechanisms of tumor immune escape. One candidate gene identified was TAP1, in …
Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy.
Zhao Y, Liu Z, Deng K, Qu H, Zhang Q, Zhou P, Yang M, Yang X, Wang H, Li R, Xia J. Zhao Y, et al. Int Immunopharmacol. 2024 May 10;132:111998. doi: 10.1016/j.intimp.2024.111998. Epub 2024 Apr 8. Int Immunopharmacol. 2024. PMID: 38593510
We assessed the potential of TAP1 as a promising therapeutic target for GC using Patient-derived organoids (PDOs)-derived xenografts (PDOXs) models of GC. ...Our findings find further confirmation in PDOX models, affirming TAP1 can enhance immunotherapy facilitated …
We assessed the potential of TAP1 as a promising therapeutic target for GC using Patient-derived organoids (PDOs)-derived xenografts …
580 results